A randomised, single-blind, placebo-controlled, single centre Phase I study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of scending single oral doses of AZD9056 tablets in healthy Japanese male patients

Study identifier:D1520C05289

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A randomised, single-blind, placebo-controlled, single centre Phase I study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of scending single oral doses of AZD9056 tablets in healthy Japanese male patients

Medical condition

Rheumatoid Arthritis

Phase

Phase 1

Healthy volunteers

-

Study drug

-

Sex

-

Actual Enrollment

-

Study type

Interventional

Age

-

Date

Study Start Date: 01 Oct 2004
Primary Completion Date: -
Study Completion Date: -

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Nov 2013 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria